Results 131 to 140 of about 4,313 (158)

Benralizumab as a potential treatment of asthma

Expert Opinion on Biological Therapy, 2017
Current anti-inflammatory asthma therapies including inhaled corticosteroids and leukotriene modifiers, are not always able to appropriately control the disease and other approaches are needed. These therapies specific target IgE (omalizumab) or IL-5 (mepolizumab).
openaire   +2 more sources

Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years

Journal of Allergy and Clinical Immunology: in Practice, 2021
Arnaud Bourdin, Borja G. Cosio, Esther García-Gil   +2 more
exaly  

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study

Journal of Clinical Medicine, 2023
Nicola Scichilone, Alessandro Vatrella, Girolamo Pelaia   +2 more
exaly  

Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma

Biomedicine and Pharmacotherapy, 2020
Giovanna E. Carpagnano, Alessandro Vatrella, Girolamo Pelaia   +2 more
exaly  

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

Chest, 2021
Brian D Kent, David J Jackson, Abdel Douiri   +2 more
exaly  

Effect of Benralizumab in Patients With Severe Eosinophilic Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Case Series

American Journal of Rhinology and Allergy, 2021
Chandala Chitguppi, Prachi Patel, Kira Murphy   +2 more
exaly  

Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis

Respiratory Medicine, 2020
Giovanni Rolla, Luisa Brussino, Marco Caminati   +2 more
exaly  

Benralizumab/omalizumab

Reactions Weekly, 2022
openaire   +2 more sources

Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

Expert Opinion on Biological Therapy, 2012
William J Calhoun, Aasia Ghazi
exaly  

Aminophylline/benralizumab

Reactions Weekly, 2023
openaire   +1 more source